Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ultragenyx Pharmaceutical Inc.

NASDAQ: RARE · Life Sciences · 7 alerts · CIK 1515673

Ultragenyx Pharmaceutical Inc. stories on ALFA USA NewsRead the news →
Share price
$16.70Close, Nov 17
Market cap
$1.7B
Shares outstanding
101.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ultragenyx Pharmaceutical Inc. filings on SEC EDGAR ↗

3:57 PM ET 8-K
Regulatory Approval

Ultragenyx Pharmaceutical Regulatory Approval

The FDA has granted standard full approval for Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf), the first-ever approved treatment for Sanfilippo syndrome Type A (MPS IIIA). This marks the company's second gene therapy approval and resulted in the receipt of a Priority Review Voucher.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.